Horváth M, Mezey Z, Jósfay A, Nánay I, Varsányi M, Geró S
Arteriosclerosis Research Group, Semmelweis Univ. Med. School, Budapest, Hungary.
J Investig Allergol Clin Immunol. 1991 Dec;1(6):404-10.
The immunomodulatory effect of the lipid-reducing etofibrate, the calcium antagonist nifedipine and the immunosuppressive cyclosporine A was studied on in vitro cellular immune response in the presence of human aortic extract and of human LDL in 56 patients with acute myocardial infarction. 50 sex- and age-matched healthy persons were used as controls. Leukocyte migration test, level of C1q and of immune complexes and serum lipid parameters were measured. Leukocyte migration inhibition was observed against aorta in 68%, against LDL in only 23% of patients, which were significantly reduced by etofibrate and nifedipine and a similar, but not significant tendency was found using cyclosporine A against aorta. Leukocyte migration stimulation was observed in 9.0% and in 27% of patients against aorta and LDL, respectively. They were also considerably decreased by etofibrate and nifedipine. A high level of circulating immune complexes was found in hyperlipemic younger patients together with lower migration inhibition against LDL, which may be explained by authors' hypothesis: LDL is a component of circulating immune complexes, so there are few free LDL for lymphokines in the circulation. A correlation between specific (anti-aorta, anti-LDL) and nonspecific (PHA) immune responses was also detected in patients. The use of these drugs may be useful in the therapy of patients with myocardial infarction in order to modulate cellular immune reactions against vascular wall and LDL.
在56例急性心肌梗死患者中,研究了降脂药物益多酯、钙拮抗剂硝苯地平和免疫抑制剂环孢素A在人主动脉提取物和人低密度脂蛋白(LDL)存在的情况下对体外细胞免疫反应的免疫调节作用。50名年龄和性别匹配的健康人作为对照。检测了白细胞迁移试验、C1q和免疫复合物水平以及血脂参数。68%的患者对主动脉出现白细胞迁移抑制,仅23%的患者对LDL出现白细胞迁移抑制,益多酯和硝苯地平可显著降低这种抑制作用,使用环孢素A对主动脉也有类似但不显著的降低趋势。分别有9.0%和27%的患者对主动脉和LDL出现白细胞迁移刺激。益多酯和硝苯地平也可使其显著降低。高脂血症年轻患者循环免疫复合物水平较高,对LDL的迁移抑制较低,作者的假设可以解释这一现象:LDL是循环免疫复合物的一个组成部分,因此循环中可被淋巴细胞因子作用的游离LDL较少。在患者中还检测到特异性(抗主动脉、抗LDL)和非特异性(PHA)免疫反应之间的相关性。使用这些药物可能有助于治疗心肌梗死患者,以调节针对血管壁和LDL的细胞免疫反应。